|ORDER ASSESSMENT TOOLS|
The Zoster BPI is a version of the Brief Pain Inventory (BPI) that is designed specifically for use with patients who have or have had herpes zoster.
In response to the US Food and Drug Administration (FDA) guidance for the pharmaceutical industry on the use of patient-reported outcome measures in medical product development to support labeling claims, we have prepared a BPI User's Guide to provide documentation of the BPI's development and psychometric properties. The information offered therein addresses the recommendations in the FDA guidance and establishes the BPI's adequacy as a measure to support medical product claims.
- Purpose: To assess the severity of pain and the impact of pain on daily functioning
- Population: Patients with pain in the region of their rash from herpes zoster
- Assessment areas: Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week
- Responsiveness: Responds to both behavioral and pharmacological pain interventions
- Method: Self-report or interview
- Time required: Five minutes (short form), 10 minutes (long form)
- Scoring: No scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference
- Reliability: Cronbach alpha reliability ranges from 0.77 to 0.91
ZBPI Language Versions
The BPI is available in the languages shown below. Click on a linked language to view a sample in PDF format.
|Psychometrically and Linguistically Validated||Linguistically Validated|
Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the ZBPI. Contact us at email@example.com for more information. NOTE: The ZBPI may not be modified or translated into another language without the express written consent of the copyright holder (see Notice of Copyright below).
To Order the ZBPI
|Type of Use||First Language Version (Per Project)||Additional Language Versions (Per Project)|
|Non-funded academic research||No charge||No charge|
|Individual clinical practice||No charge||No charge|
|Funded academic research||$300||$150|
The ZBPI will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:
The Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."
The Brief Pain Inventory (BPI) copyright is held by Dr. Charles S. Cleeland (1991). The copyright applies to the BPI and all its derivatives in any language.
The ZBPI may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).
The BPI may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at firstname.lastname@example.org or at the address shown above to obtain permission to alter or translate the instrument.
Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 5(6): 344-356, 2004.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2): 129-138, 1994.
Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Advances in Pain Research and Therapy, Volume 12: Issues in Pain Measurement. New York: Raven Press; 1989. pp. 391-403.
Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20(5): 309-318, 2004.
Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, Rabaud C, Rogeaux O, Strady C. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 153(2): 342-349, 2012.
Duracinsky M, Paccalin M, Gavazzi G, El Kebir S, Gaillat J, Strady C, Bouhassira D, Chassany O. ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients? BMC Infect Dis 14: 529, 2014.
Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis 14: 402, 2014
Laurent B, Vicaut E, Leplège A, Bloch K, Leutenegger E. Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: the ZOCAD study. Med Mal Infect 44(11-12): 515-524, 2014.
Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New Engl J Med 352(22): 2271-2284, 2005.
Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriat Soc 58(9): 1634-1641, 2010.
Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 23(6): 490-496, 2007.
Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes 12: 92, 2014.
Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan IS, Silber JL, Parrino J, Levin MJ. Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects. Clin Vaccine Immunol 19(9) 1411-1415, 2012.